Alphamab Oncology

Glycan-specific Conjugation Platform
Bispecific Antibody Platform
Subcutaneous Formulation Platform

Revolutionary Technology in Cancer Therapeutics

This platform leverages antibody Fc glycan-specific conjugation technology, utilizing an innovative one-enzyme two-step method that simplifies processes and reduces costs. It enables the development of ADCs with highly uniform DAR, demonstrating superior serum stability, enhanced bystander effects, and a broader therapeutic window, while minimizing toxicity risks. The platform has been validated for industrial-scale production and is currently expanding to develop dual-payload ADCs with customizable DAR values. Additionally, it can be integrated with other conjugation technologies, such as thiol-based conjugation and microbial transglutaminase (mTG), to generate a diverse array of next-generation ADCs.

Learn More

Globally Leading Bispecific Antibody Development Platform

This platform integrates two core technologies: the Fc-based CRIB (Charge Repulsion Induced Bispecific) heterodimer platform and the single-domain antibody assembly platform. The CRIB technology overcomes critical CMC (Chemistry, Manufacturing, and Control) challenges in asymmetric bispecific antibody production, enabling stable manufacturing of high-purity bispecific antibodies. The single-domain antibody assembly technology allows flexible construction of quadrivalent symmetric bispecific antibodies, which enhance tumor targeting precision through dual-target synergy while minimizing off-target risks. The platform’s advantages have been validated across multiple product candidates.

Learn More

Innovation in Drug Administration Technology

Subcutaneous high concentration formulation platform has successfully overcome technical barriers in developing high-concentration (≥150 mg/mL) liquid formulations for antibody drugs, enabling long-term stable storage (24-month stability under 2-8℃conditions). It has completed the commercial formulation development for products such as KN035 (PD-L1 single-domain antibody), with patient compliance surveys showing a satisfaction rate of 92%. For ADCs, the platform offers subcutaneous formulations that reduce infusion reactions (incidence lowered to <5%) and hematologic toxicity associated with intravenous administration.

Learn More

Company

Overview

Board of Directors

Partnering

Technology

Glycan-specific Conjugation

Alphatecan

Bispecific Antibody

Subcutaneous Formulation

Single-domain Antibody

Publications

Pipeline

Overview

Envafolimab(KN035)

KN026

JSKN003

JSKN016

JSKN033

KN046

KN019

Investors

Information Disclosure

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

News

Press Release

Media Report

Career

Corporate Culture

Job Opportunities

Contact Us

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : To develop differentiated, clinically valuable and globally competitive new drugs

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Revolutionary Technology in Cancer Therapeutics

Globally Leading Bispecific Antibody Development Platform

Innovation in Drug Administration Technology

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable Our Vision : To develop differentiated, clinically valuable and globally competitive new drugs Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Revolutionary Technology in Cancer Therapeutics

Globally Leading Bispecific Antibody Development Platform

Innovation in Drug Administration Technology

Our Mission : To make cancer manageable and curable

Our Vision : To develop differentiated, clinically valuable and globally competitive new drugs

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth